Increased soluble programed cell death-ligand 1 is associated with acute coronary syndrome. (15th February 2022)

• Record Type: Journal Article
• Authors: Fujisue, Koichiro; Yamamoto, Eiichiro; Sueta, Daisuke; Takae, Masafumi; Nishihara, Taiki; Komorita, Takashi; Usuku, Hiroki; Yamanaga, Kenshi; Ito, Miwa; Hoshiyama, Tadashi; Kanazawa, Hisanori; Takashio, Seiji; Arima, Yuichiro; Araki, Satoshi; Soejima, Hirofumi; Kaikita, Koichi; Matsushita, Kenichi; Tsujita, Kenichi
• Is Part Of: International journal of cardiology. Volume 349(2022)
• Page Start: 1
• Page End: 6
• Publication Date: 2022-02-15
• Subjects: Soluble programmed cell death-ligand 1 -- Immune checkpoint pathways -- Acute coronary syndrome -- Chronic coronary syndrome; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2021.11.060
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: Programmed cell death (PD)-1 and its ligand (PD-L1) plays crucial roles in T-cell tolerance as immune checkpoint. Previous studies reported that increased serum levels of soluble PD-L1 (sPD-L1) reflect myocardial and vascular inflammation. However, little is known about the clinical relationship between sPD-L1 and acute coronary syndrome (ACS). We investigated the relation of sPD-L1 and ACS. Methods: We prospectively measured serum levels of sPD-L1 using a commercially available enzyme-linked immunosorbent assay kit in patients with coronary artery disease (CAD) and continuous non-CAD admitted to Kumamoto University Hospital between December 2017 and June 2019. All malignant diseases, patients who underwent hemodialysis, active collagen diseases, and severe infectious diseases were excluded. Results: Totally, 446 CAD patients [ACS, n = 124; chronic coronary syndrome (CCS), n = 322] and 24 non-CAD patients were analyzed. The levels of sPD-L1 were significantly higher in patients with ACS than those both with non-CAD and CCS {ACS, 188.7 (111.0–260.8) pg/mL, p < 0.001 vs. non-CAD [83.5 (70.8–130.4) pg/mL]; and p = 0.009 vs. CCS [144.2 (94.8–215.5) pg/mL], respectively}. Univariate logistic regression analysis identified that sPD-L1 was significantly associated with ACS [odds ratio (OR): 1.459, 95% confidence interval (CI): 1.198–1.778, p < 0.001]. Multivariable logistic regression analysis with nine significant factors identified from the univariate analysis revealed that sPD-L1 was significantly and independently associated with ACS (OR: 1.561, 95% CI: 1.215–2.006, p < 0.001). Conclusions: This is the first clinical study to demonstrate the increased level of sPD-L1 in patients with CAD, and the significant association with ACS. Highlights: This study evaluated serum levels of soluble PD-L1 (sPD-L1) in CAD patients. CAD patients showed higher levels of sPD-L1 than those without CAD. The increased levels of sPD-L1 were associated with acute coronary syndrome.